好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Adult-onset Biotinidase Deficiency with Partial Remission Misdiagnosed as NMO
Autoimmune Neurology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
2-010

Biotinidase deficiency (BD) is an autosomal recessive metabolic disorder that can present atypically in adulthood and mimic demyelinating disorders. We present a case of adult-onset BD with a relapsing course initially diagnosed as neuromyelitis optica spectrum disorder (NMOSD) and treated with immunosuppressive therapy for over a decade.

N/A
This is a case report of a 33-year-old male who presented with acute-onset proximal leg weakness, foot paresthesias, diplopia, and scotoma in 2011, followed by a relapsing course over 13 years despite immunosuppressive therapy.

Initial brain and spine MRI showed minimal findings with punctate T2 hyperintensities. CSF analysis was consistently unremarkable with negative oligoclonal bands and negative NMO/MOG antibodies. The patient symptomatically responded to corticosteroids, plasmapheresis, and rituximab therapy, but remained wheelchair dependent. After 13 years of presumed stable inflammatory demyelinating disease, serum biotinidase activity was found to be markedly deficient (<0.5 U/L; normal 4.4-12.0 U/L) following progression of symptoms. Genetic testing confirmed two pathogenic variants in the BTD gene: c.1612C>T (p.Arg538Cys) and c245C> (p.Ala82Val). Oral biotin supplementation was initiated with improvement in multiple symptoms.

Adult-onset BD can mimic demyelinating disorders, particularly when presenting with optic neuropathy and myelopathy. This case highlights the importance of considering metabolic disorders in atypical presentations of presumed demyelinating conditions, as early diagnosis and inexpensive biotin supplementation can prevent unnecessary immunosuppressive therapy and irreversible neurological damage.

Authors/Disclosures
Margarita Fedorova, MD (Electric Gardens)
PRESENTER
Ms. Fedorova has nothing to disclose.
Abigail Kacpura, DO Dr. Kacpura has nothing to disclose.
Amy S. Babiuch, MD Dr. Babiuch has received personal compensation for serving as an employee of Genentech.
Robert A. Bermel, MD, FAAN (Cleveland Clinic) Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care.
Gregory S. Kosmorsky, DO Dr. Kosmorsky has nothing to disclose.
Nirmal Andrapalliyal, MD (Cleveland Clinic) Dr. Andrapalliyal has nothing to disclose.